Supply Chain
Drug Pricing
Wayne Winegarden – Why the Pelosi and Newsom Approaches to Prescription Drugs Won’t Really Help Patients
Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, breaks down recently-proposed plans in Washington and Sacramento that emphasize price caps and more government control to address prescription drug prices. He discusses the conclusions of his new study on America’s drug pricing challenge, which makes the case ...
Blog
Taxpayers Exhausted from Newsom’s Marathon Budget Presser
Gov. Newsom’s announcement of his 2020-21 State Budget plan on Friday was another whopper, his speech clocking in at roughly 2 hours and 47 minutes. Last year, reporters who were used to covering a 30 minute press conference where caught off guard by Newsom’s lengthy presentation. Los Angeles Times reporter ...
Drug Pricing
NEW STUDY shows that Reforming Supply Chain & Drug Pricing System Will Lower Health Care Costs
As Washington pushes for price caps and government controls to address prescription drug prices, a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute argues that reforming the complex drug supply chain and ending the current drug pricing system that overcharges ...
Commentary
To Help Patients, Reform The Drug Pricing System Don’t Impose Price Controls
Yesterday the House passed the ill-considered “Pelosi bill” that would impose draconian price controls on drugs. Ignoring the bill’s many adverse impacts, price control advocates like Speaker Pelosi appear to believe that these command and control schemes can solve the systemic health care affordability problem. But, as the latest government data illustrates, ...
Commentary
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Agriculture
Organic Industry Anti-Pesticide Propaganda Threatens to Cripple American Agriculture
In The Wealth of Nations, the 18th century economist and philosopher Adam Smith observed about the chicanery of some businessmen, “People of the same trade seldom meet together, even for merriment and diversion, but the conversation ends in a conspiracy against the public, or in some contrivance to raise prices.” ...
Commentary
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Commentary
Wayne Winegarden in Forbes: Inflation Caps Are Price Controls By Another Name
From the time we were toddlers, it has always been tempting to bang the square peg into the round hole. After all, there is always that one square peg that seems like it should just about fit into that round hole, and it would feel so satisfying if it did. ...
Commentary
Trump Scraps A Reform That Would Have Saved Patients Billions
This week, the Trump administration axed a proposal that would have saved American patients billions of dollars by shedding light on the complex drug supply chain. If enacted, the rule would have required insurers to share discounts they negotiate with drug companies directly with patients. The proposed rule would have changed the ...
Commentary
Rebate Rule Will Save Patients Billions
President Trump promised to reduce Americans’ pharmacy bills — and he’s delivering. His administration will soon finalize a rule that restructures the drug supply chain and ensure that tens of billions of dollars of hidden rebates and discounts flow to patients. The rule affects Medicare Part D, the federal prescription ...
Wayne Winegarden – Why the Pelosi and Newsom Approaches to Prescription Drugs Won’t Really Help Patients
Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, breaks down recently-proposed plans in Washington and Sacramento that emphasize price caps and more government control to address prescription drug prices. He discusses the conclusions of his new study on America’s drug pricing challenge, which makes the case ...
Taxpayers Exhausted from Newsom’s Marathon Budget Presser
Gov. Newsom’s announcement of his 2020-21 State Budget plan on Friday was another whopper, his speech clocking in at roughly 2 hours and 47 minutes. Last year, reporters who were used to covering a 30 minute press conference where caught off guard by Newsom’s lengthy presentation. Los Angeles Times reporter ...
NEW STUDY shows that Reforming Supply Chain & Drug Pricing System Will Lower Health Care Costs
As Washington pushes for price caps and government controls to address prescription drug prices, a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute argues that reforming the complex drug supply chain and ending the current drug pricing system that overcharges ...
To Help Patients, Reform The Drug Pricing System Don’t Impose Price Controls
Yesterday the House passed the ill-considered “Pelosi bill” that would impose draconian price controls on drugs. Ignoring the bill’s many adverse impacts, price control advocates like Speaker Pelosi appear to believe that these command and control schemes can solve the systemic health care affordability problem. But, as the latest government data illustrates, ...
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Organic Industry Anti-Pesticide Propaganda Threatens to Cripple American Agriculture
In The Wealth of Nations, the 18th century economist and philosopher Adam Smith observed about the chicanery of some businessmen, “People of the same trade seldom meet together, even for merriment and diversion, but the conversation ends in a conspiracy against the public, or in some contrivance to raise prices.” ...
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Wayne Winegarden in Forbes: Inflation Caps Are Price Controls By Another Name
From the time we were toddlers, it has always been tempting to bang the square peg into the round hole. After all, there is always that one square peg that seems like it should just about fit into that round hole, and it would feel so satisfying if it did. ...
Trump Scraps A Reform That Would Have Saved Patients Billions
This week, the Trump administration axed a proposal that would have saved American patients billions of dollars by shedding light on the complex drug supply chain. If enacted, the rule would have required insurers to share discounts they negotiate with drug companies directly with patients. The proposed rule would have changed the ...
Rebate Rule Will Save Patients Billions
President Trump promised to reduce Americans’ pharmacy bills — and he’s delivering. His administration will soon finalize a rule that restructures the drug supply chain and ensure that tens of billions of dollars of hidden rebates and discounts flow to patients. The rule affects Medicare Part D, the federal prescription ...
